SV Health Investors, Samsara BioCapital and Jeito Capital led a $65m Series A round in EyeBio.

SV Health Investors, an investment firm, Samsara BioCapital, a venture capital firm, and Jeito Capital, a private equity general partner firm, led a $65m Series A round in EyeBio, a privately held ophthalmology biotechnology company, with participation from MRL Ventures. “Advances in research are revealing new opportunities to translate science into solutions that serve patients with eye diseases who have urgent and unaddressed medical needs. Patients and physicians deserve new and better solutions, which is why this team of serial disruptors has banded together to form EyeBio. We are launching at an exciting time, and we are equipped with the resources to make a significant impact,” David Guyer, EyeBio Co-Founder, President, and Chief Executive Officer.